MedCity News January 21, 2026
Pfizer’s stake in ViiV Healthcare will be taken over by Shiongi, another minority shareholder in the HIV medicines company. GSK remains remain the majority shareholder in ViiV, which the pharmaceutical giant formed in partnership with Pfizer in 2009.
Pfizer is getting out of the business of developing and marketing HIV medicines by exiting its minority stake in ViiV Healthcare, a company the pharmaceutical giant formed in partnership with GSK 17 years ago.
Under a new agreement, Pfizer’s ownership in ViiV will be replaced by Shionogi, another minority shareholder of the HIV company. According to deal terms announced Tuesday, ViiV is canceling Pfizer’s 11.7% stake in the company and Pfizer will receive $1.875 billion. Meanwhile, ViiV will issue new shares to...
Today's Sponsors
Today's Sponsor